公开(公告)号：US12049439B2

公开(公告)日：2024-07-30

申请号：US17463011

申请日：2021-08-31

申请人： OrsoBio, Inc.

发明人： Julie Farand ,  Joshua A. Kaplan ,  Gregory Notte ,  Casey Lockwood Olen ,  Michael Sangi ,  David Sperandio

IPC分类号： C07C323/25 ,  A61K31/18 ,  A61P1/16 ,  C07C311/08 ,  C07C311/13 ,  C07C311/14 ,  C07C311/21 ,  C07C311/29 ,  C07C311/39 ,  C07C311/46 ,  C07C313/06 ,  C07C323/30 ,  C07C323/31 ,  C07D205/04 ,  C07D207/48 ,  C07D213/89 ,  C07D231/18 ,  C07D235/00 ,  C07D239/26 ,  C07D257/04 ,  C07D275/02 ,  C07D277/36 ,  C07D279/12 ,  C07D295/116 ,  C07D305/08 ,  C07D309/08 ,  C07D335/02 ,  C07D451/02 ,  C07D493/08 ,  C07F9/50

CPC分类号： C07C323/25 ,  A61K31/18 ,  A61P1/16 ,  C07C311/08 ,  C07C311/13 ,  C07C311/14 ,  C07C311/21 ,  C07C311/29 ,  C07C311/39 ,  C07C311/46 ,  C07C313/06 ,  C07C323/30 ,  C07C323/31 ,  C07D205/04 ,  C07D207/48 ,  C07D213/89 ,  C07D231/18 ,  C07D235/00 ,  C07D239/26 ,  C07D257/04 ,  C07D275/02 ,  C07D277/36 ,  C07D279/12 ,  C07D295/116 ,  C07D305/08 ,  C07D309/08 ,  C07D335/02 ,  C07D451/02 ,  C07D493/08 ,  C07F9/5022

摘要： Provided is a compound of Formula (I):






wherein the variable groups are defined herein.

公开(公告)号：US20240192236A1

公开(公告)日：2024-06-13

申请号：US18523548

申请日：2023-11-29

申请人： ARK Diagnostics, Inc.

发明人： Johnny Jose Valdez ,  Byung Sook Moon ,  Michael Kevin Helms ,  Alejandro A. Orozco

IPC分类号： G01N33/94 ,  A61K39/00 ,  C07C229/28 ,  C07C233/36 ,  C07C233/47 ,  C07C321/04 ,  C07C323/25 ,  C07K16/44 ,  G01N33/53

CPC分类号： G01N33/9473 ,  C07C229/28 ,  C07C233/36 ,  C07C233/47 ,  C07C321/04 ,  C07C323/25 ,  C07K16/44 ,  G01N33/53 ,  G01N33/5308 ,  A61K2039/505 ,  A61K2039/60 ,  C07C2601/12 ,  C07C2601/14

摘要： Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

公开(公告)号：US20240150306A1

公开(公告)日：2024-05-09

申请号：US18373890

申请日：2023-09-27

申请人： REINVIGORON THERATECH, INC.

发明人： Kejin ZHOU

IPC分类号： C07D295/15 ,  C07C323/25 ,  C07D295/088

CPC分类号： C07D295/15 ,  C07C323/25 ,  C07D295/088

摘要： Provided herein are compounds having one or more cleavable disulfide moieties and one or more hydrophobic tail moieties (HTM) for delivery of one or more therapeutic or diagnostic agents. In some embodiments, the one or more therapeutic or diagnostic agents are biologics. In some embodiments, the one or more therapeutic or diagnostic agents are delivered to cancer cells.

公开(公告)号：US20230381319A1

公开(公告)日：2023-11-30

申请号：US18110791

申请日：2023-02-16

申请人： ARBUTUS BIOPHARMA CORPORATION

发明人： Muthiah Manoharan ,  Kallanthottathil G. Rajeev ,  Muthusamy Jayaraman ,  David Butler ,  Jayaprakash K. Nair ,  Martin Maier ,  Laxman Eltepu

IPC分类号： A61K47/44 ,  A61K39/39 ,  C07C229/08 ,  A61K31/713 ,  C07D319/06 ,  C07D317/28 ,  C07D203/10 ,  C07C229/30 ,  C12N15/113 ,  A61K39/00 ,  C12N15/11 ,  A61K9/127 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/28 ,  C07C237/16 ,  C07C251/38 ,  C07C251/78 ,  C07C271/12 ,  C07C271/20 ,  C07C323/25 ,  A61K31/7088 ,  C07D317/44 ,  C07D317/46 ,  C07D317/72 ,  C07D405/12 ,  C07D491/056 ,  C07D491/113

CPC分类号： A61K47/44 ,  A61K39/39 ,  C07C229/08 ,  A61K31/713 ,  C07D319/06 ,  C07D317/28 ,  C07D203/10 ,  C07C229/30 ,  C12N15/113 ,  A61K39/00 ,  C12N15/111 ,  A61K9/1272 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/28 ,  C07C237/16 ,  C07C251/38 ,  C07C251/78 ,  C07C271/12 ,  C07C271/20 ,  C07C323/25 ,  A61K31/7088 ,  C07D317/44 ,  C07D317/46 ,  C07D317/72 ,  C07D405/12 ,  C07D491/056 ,  C07D491/113 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2310/14 ,  C12N2310/3515 ,  C12N2320/32 ,  Y02A50/30

摘要： The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.

公开(公告)号：US20230174562A1

公开(公告)日：2023-06-08

申请号：US17923831

申请日：2021-05-07

申请人： TONIX PHARMACEUTICALS, INC. ,  TONIX PHARMACEUTICALS HOLDING CORP.

发明人： Philip S. Schein ,  Darryl C. Rideout

IPC分类号： C07F9/165 ,  A61K45/06 ,  A61P39/00 ,  A61K31/661 ,  C07D243/08 ,  A61K31/551 ,  C07D241/04 ,  A61K31/495 ,  C07D243/10 ,  C07D245/02 ,  A61K31/395 ,  C07D245/04 ,  C07D487/04 ,  A61K31/4985 ,  C07C53/18 ,  C07D241/38 ,  A61K31/498 ,  C07F9/6571 ,  A61K31/675 ,  C07C323/25 ,  A61K31/145

CPC分类号： C07F9/1651 ,  A61K45/06 ,  A61P39/00 ,  A61K31/661 ,  C07D243/08 ,  A61K31/551 ,  C07D241/04 ,  A61K31/495 ,  C07D243/10 ,  C07D245/02 ,  A61K31/5545 ,  C07D245/04 ,  C07D487/04 ,  A61K31/4985 ,  C07C53/18 ,  C07D241/38 ,  A61K31/498 ,  C07F9/657118 ,  A61K31/675 ,  C07C323/25 ,  A61K31/145 ,  C07B2200/13

摘要： The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methy-lamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.

公开(公告)号：US11643419B2

公开(公告)日：2023-05-09

申请号：US16339431

申请日：2017-04-19

申请人： Cellix Bio Private Limited

发明人： Mahesh Kandula

IPC分类号： A61K31/4178 ,  A61K31/385 ,  C07D405/06 ,  C07D339/04 ,  C07D497/20 ,  A61K9/00 ,  C07C229/08 ,  C07C323/25 ,  C07F9/06

CPC分类号： C07D497/20 ,  A61K9/0053 ,  C07C229/08 ,  C07C323/25 ,  C07D405/06 ,  C07F9/06

摘要： The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.

公开(公告)号：US20180305308A1

公开(公告)日：2018-10-25

申请号：US15767966

申请日：2015-10-14

申请人： PHARMALEADS

发明人： Herve PORAS ,  Loic LEFEBVRE ,  Xinjun ZHAO ,  Luca GAMBERONI ,  Sabrina DE ROSA ,  Rosario VELARDI

IPC分类号： C07C323/25 ,  C07D215/26 ,  B01J19/18

CPC分类号： C07C323/25 ,  B01J19/1862 ,  B01J2219/00029 ,  B01J2219/0004 ,  C07B2200/07 ,  C07C319/02 ,  C07C319/22 ,  C07C319/24 ,  C07C319/28 ,  C07C323/40 ,  C07C327/32 ,  C07D215/26 ,  C07C323/60 ,  C07C323/56

摘要： The present invention relates to an industrial process for the preparation of (5S,10S)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt of following formula (I): wherein X is fumarate. This process comprises the following successive key steps: a kinetic resolution, formation of disulfide compound, peptide coupling, and anion exchange reaction to obtain the desired product of formula (I).

公开(公告)号：US20180177881A1

公开(公告)日：2018-06-28

申请号：US15821368

申请日：2017-11-22

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Jordan J. Green ,  Joel C. Sunshine ,  Nupura S. Bhise ,  Ron B. Shmueli ,  Stephany Y. Tzeng

IPC分类号： A61K47/20 ,  C12N15/88 ,  C08G73/02 ,  C07C323/25 ,  A61K31/713 ,  C08F222/10 ,  A61K9/107 ,  C07C229/12 ,  A61K38/02 ,  A61K48/00

CPC分类号： A61K47/20 ,  A61K9/1075 ,  A61K31/713 ,  A61K38/02 ,  A61K48/00 ,  C07C229/12 ,  C07C323/25 ,  C08F222/1006 ,  C08F2222/1013 ,  C08G73/028 ,  C12N15/88

摘要： Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.

公开(公告)号：US20180155609A1

公开(公告)日：2018-06-07

申请号：US15829576

申请日：2017-12-01

申请人： Ecolab USA Inc.

发明人： Boyd Anthony Laurent ,  Prakasa Rao Anantaneni ,  Ryan Matthew Harrington ,  Subhasis De

IPC分类号： C09K8/54 ,  C09K15/12 ,  C07C323/12 ,  C07C323/52 ,  C07C323/25

CPC分类号： C09K8/54 ,  C07C323/12 ,  C07C323/25 ,  C07C323/52 ,  C09K15/12 ,  C09K2208/32

摘要： The present invention generally relates to compositions and methods for inhibiting corrosion at a surface in the production, transportation, storage, and separation of crude oil and natural gas.

公开(公告)号：US09988415B2

公开(公告)日：2018-06-05

申请号：US15060152

申请日：2016-03-03

申请人： BONAC CORPORATION

发明人： Eriko Aoki ,  Hiroshi Suzuki ,  Akihiro Itoh

IPC分类号： C07C323/25 ,  C07C323/12 ,  C07C319/16 ,  C07C319/20 ,  C07C319/14 ,  C07H19/06 ,  C07H21/00 ,  C07H23/00 ,  C07H1/00 ,  C07H19/16 ,  C07H19/167 ,  C07H19/067

CPC分类号： C07H19/06 ,  C07C319/14 ,  C07C319/16 ,  C07C319/20 ,  C07C323/12 ,  C07C323/25 ,  C07H1/00 ,  C07H19/067 ,  C07H19/16 ,  C07H19/167 ,  C07H21/00 ,  C07H23/00 ,  Y02P20/55

摘要： The invention provides a glucoside compound, which is capable of providing a phosphoramidite, which can be produced at low cost and can produce a nucleic acid in high yield and with high purity. The glycoside compound has the formula wherein B, R1, R2, and R3 are as described herein.